Early health technology assessments in pharmacogenomics: a case example in cardiovascular drugs
Publication date
2017-08
Authors
Geenen, Joost W
Baranova, Ekaterina V.
Asselbergs, Folkert W
de Boer, Anthonius
Vreman, Rick A.
Palmer, Colin Na
Maitland-van der Zee, Anke-Hilse
Hövels, Anke M.
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
taverne
Abstract
AIM: To assess the required characteristics (cost, sensitivity and specificity) of a pharmacogenomic test for being a cost-effective prevention of angiotensin-converting enzyme inhibitors induced angioedema. Furthermore, we assessed the influence of only testing high-risk populations. MATERIALS & METHODS: A decision tree was used. RESULTS: With a willingness-to-pay threshold of €20,000 and €80,000 per quality adjusted life year, a 100% sensitive and specific test may have a maximum cost of €1.30 and €1.95, respectively. When only genotyping high-risk populations, the maximum test price would be €5.03 and €7.55, respectively. CONCLUSION: This theoretical pharmacogenomic test is only cost-effective at high specificity, high sensitivity and a low price. Only testing high-risk populations yields more realistic maximum test prices for cost-effectiveness of the intervention.
Keywords
adverse drug reactions, angioedema, ACE inhibitors, ACE inhibitor induced angioedema, cardiovascular drugs, health technology assessment, pharmacogenomic test, Taverne, SDG 3 - Good Health and Well-being
Citation
Geenen, J W, Baranova, E V, Asselbergs, F W, de Boer, A, Vreman, R A, Palmer, C N, Maitland-van der Zee, A H & Hövels, A M 2017, 'Early health technology assessments in pharmacogenomics : a case example in cardiovascular drugs', Pharmacogenomics, vol. 18, no. 12, pp. 1143-1153. https://doi.org/10.2217/pgs-2017-0063